BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This highly advanced multi-functional targeted formulation features YIGSR peptide functionalized liposomes co-loaded with doxorubicin and 5-fluorouracil. The structural framework encapsulates the hydrophilic anthracycline doxorubicin alongside the fluorinated pyrimidine analogue 5-fluorouracil (5F) entirely within its central aqueous core reservoirs, while its exterior lipid bilayer boundary is surface-modified with specific laminin-derived tyrosine-isoleucine-glycine-serine-arginine (YIGSR) targeting pentapeptides linked via polymer-lipid anchors. This complex surface configuration coordinates a dense target-mimetic ligand array with an optimized multi-cargo matrix, altering overall surface hydration parameters to completely prevent physical vesicle aggregation while restricting passive drug leakage.
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.